Sergio Tanganelli Selected Research

Parkinson Disease (Parkinson's Disease)

1/2018	Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors.
1/2014	Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.
1/2014	Understanding the role of heteroreceptor complexes in the central nervous system.
1/2014	Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
5/2013	Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers.
10/2012	A(2A)/D(2) receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling.
8/2008	Neurotensin receptors as modulators of glutamatergic transmission.
6/2008	Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
10/2006	Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sergio Tanganelli Research Topics

Disease

9	Schizophrenia (Dementia Praecox) 01/2020 - 08/2007
9	Parkinson Disease (Parkinson's Disease) 01/2018 - 10/2006
3	Cognitive Dysfunction 01/2020 - 07/2014
1	Alzheimer Disease (Alzheimer's Disease) 01/2018
1	Neurobehavioral Manifestations 01/2017
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2016
1	Alcoholism (Alcohol Abuse) 10/2013
1	Fatigue 04/2013
1	Sleep Wake Disorders 04/2013
1	Sleepiness 04/2013
1	Narcolepsy 04/2013
1	Huntington Disease (Huntington's Disease) 03/2012
1	Dyskinesias (Dyskinesia) 10/2006
1	Memory Disorders (Memory Loss) 04/2003

Drug/Important Bio-Agent (IBA)

9	gamma-Aminobutyric Acid (GABA)IBA 04/2016 - 10/2006
6	Adenosine (Adenocard)FDA LinkGeneric 01/2020 - 10/2012
5	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 10/2012
4	Glutamic Acid (Glutamate)FDA Link 01/2017 - 04/2003
3	Protein Subunits (Protein Subunit)IBA 01/2020 - 01/2014
3	CannabinoidsIBA 03/2017 - 06/2008
3	NeurotensinIBA 01/2017 - 05/2013
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2018
1	LipidsIBA 01/2018
1	palmidrolIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2017
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2017
1	Serotonin (5 Hydroxytryptamine)IBA 01/2017
1	Aminobutyrates (Aminobutyric Acid)IBA 04/2016
1	N-Methylaspartate (NMDA)IBA 04/2016
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 04/2016
1	Glutamate Receptors (Glutamate Receptor)IBA 04/2016
1	Antipsychotic Agents (Antipsychotics)IBA 01/2014
1	Modafinil (Provigil)FDA Link 04/2013
1	Neuroprotective AgentsIBA 08/2008
1	Oxidopamine (6 Hydroxydopamine)IBA 08/2008
1	SR 48692IBA 08/2008
1	Levodopa (L Dopa)FDA LinkGeneric 10/2006
1	Cannabinoid Receptor AgonistsIBA 04/2003

Therapy/Procedure

1	Continuous Positive Airway Pressure 04/2013
1	Therapeutics 08/2009